All relevant data are within the paper and its Supporting Information file.

Introduction {#sec001}
============

*Escherichia coli* is the most common Gram-negative bacteria to cause various infection syndromes in humans, including urinary tract infections (UTI), bacteremia, meningitis, and gastrointestinal illnesses \[[@pone.0144103.ref001]\]. It is the leading cause of UTI and accounts for 70--95% of community-onset UTI cases \[[@pone.0144103.ref002]\]. Timely administration of effective antibiotics plays a key role in resolution of bacterial infections \[[@pone.0144103.ref003], [@pone.0144103.ref004]\]. Fluoroquinolones and third generation cephalosporins are two groups of antibiotics usually recommended by therapeutic guidelines for treating infections caused by *Enterobacteriaceae*, including *E*. *coli* \[[@pone.0144103.ref005], [@pone.0144103.ref006]\], whereas nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin, may be considered for the treatment of uncomplicated and community-acquired UTI depending on the prevalence of resistance \[[@pone.0144103.ref005], [@pone.0144103.ref007]\].

Resistance to fluoroquinolones (FQ) and third-generation cephalosporins has increased significantly in clinical isolates of *E*. *coli* \[[@pone.0144103.ref008], [@pone.0144103.ref009]\]. A leading cause contributing to the increase of drug resistance has been dissemination of extended-spectrum β-lactamase (ESBL)---and/or AmpC β-lactamase-producers \[[@pone.0144103.ref010]--[@pone.0144103.ref013]\]. However, the prevalence of antimicrobial resistance can vary substantially between countries and regions. For example, ESBL-producers accounted for 5.9% of community-associated UTI *E*. *coli* isolated during 2009--2011 in the US \[[@pone.0144103.ref008]\], while it ranged 1.8% to 25.2% in *E*. *coli* isolated during 2004--2010 in Eastern European countries \[[@pone.0144103.ref014]\]. Information on the prevalence of AmpC-producers in clinical *E*. *coli* isolates is limited, but has been reported to be low, at 1.1% in Spain and 2% in China on isolates from 2010--2011 \[[@pone.0144103.ref015], [@pone.0144103.ref016]\]. A recent global surveillance study on gram-negative pathogens causing UTI isolated during 2009--2011 from different countries found FQ resistance to vary widely with a range of 6% in Estonia and 75% in India \[[@pone.0144103.ref017]\]. In Europe, the overall FQ non-susceptibility of *E*. *coli* isolates from 2013 also varied considerably between countries, from 11.7% in Norway to 51.9% in Cyprus \[[@pone.0144103.ref018]\]. Such variations highlight the need for surveillance in each country to define the extent of the problem and help identify unusual resistance problems that exist locally \[[@pone.0144103.ref003]\]. These data can also impact empirical therapy practices in each country.

Most studies, including some of the data mentioned above focused on isolates from hospitalized patients or do not differentiate inpatient and outpatient source. Longitudinal nationwide surveillance data on antimicrobial resistance of *E*. *coli* from community settings are limited and the isolates surveyed are mostly from urinary tract infections \[[@pone.0144103.ref019], [@pone.0144103.ref020]\]. In addition, the prevalence of ESBL and AmpC β-lactamases-producers in *E*. *coli* isolates from the community setting are scarce. The effect of the 2014 Clinical and Laboratory Standards Institute (CLSI) revised interpretive criteria on cefazolin for *E*. *coli* isolates from urine, on cefepime for Enterobacteriaceae \[[@pone.0144103.ref021]\] and on *E*. *coli* non-susceptibility from our region is also unknown. The Taiwan Surveillance of Antimicrobial Resistance (TSAR) is a biennial multicenter program conducted at the National Health Research Institutes \[[@pone.0144103.ref022], [@pone.0144103.ref023]\]. The present study analyzed the TSAR data from 2002 to 2012 on *E*. *coli* from different sources in the community setting to address the aforementioned issues.

Methods {#sec002}
=======

Isolate collection {#sec003}
------------------

*E*. *coli* isolates were collected as part of the TSAR program conducted biennially between 2002 and 2012 (corresponding to TSAR III--VIII). Isolates were collected from medical centers and regional hospitals, including a total number of 28 hospitals located in the 4 geographic regions of Taiwan following previously described protocol \[[@pone.0144103.ref023]\]. All isolates were stored at −70°C. Only *E*. *coli* clinical isolates from outpatients and patients visiting emergency rooms were enrolled in the present study. The TSAR project was approved by the Research Ethics Committee of National Health Research Institutes, Taiwan (EC960205 and EC1010602-E). Written informed consent was not obtained because the study only used bacterial isolates recovered from clinical samples taken as part of standard care and patient information was anonymized and de-identified prior to analysis.

Isolate identification {#sec004}
----------------------

Clinical isolates reported to be *E*. *coli* by hospitals were first subcultured to blood agar and MacConkey agar plates for purity check. Species confirmation was based on colony morphology, positive spot indole and β-glucuronidase \[[@pone.0144103.ref024], [@pone.0144103.ref025]\]. For isolates not typical of *E*. *coli* colony morphology or if negative for either of the above biochemical reactions, Vitek II GN cards were used (bioMérieux, Marcy l'Etoile, France).

Antimicrobial susceptibility testing (AST) {#sec005}
------------------------------------------

Minimum inhibitory concentrations (MICs) were determined using reference broth microdilution method following the guidelines of the manufacturer and CLSI \[[@pone.0144103.ref021]\]. Sensititre custom-designed plates were used from TSAR III (2002) to TSAR VI (2008), and the standard GNX2F plates were used in TSAR VII (2010) and TSAR VIII (2012) \[ThermoFisher Scientific (formerly Trek Diagnostics), East Grinstead, UK\]. All isolates were subcultured twice on sheep blood agar plate from -70°C before AST. Quality control was performed using *E*. *coli* ATCC 25922, *E*. *coli* ATCC 35218, *Klebsiella pneumoniae* ATCC 700603, and *Pseudomonas aeruginosa* ATCC 27853.

The following antimicrobial agents were tested on isolates from all study years: amikacin, ampicillin, aztreonam, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, cefuroxime, ciprofloxacin, gentamicin, and imipenem. Other agents not tested in all years included (years tested) amoxicillin/clavulanate (2002--2008), ertapenem (2012), nitrofurantoin (2002--2006, and 2012 on urine isolates), piperacillin (2002--2010), tetracycline (2002--2008), tigecycline (2010 and 2012), Fosfomycin was tested on 2012 isolates from urine only by the agar dilution method using Mueller-Hinton agar supplemented with 25 mg/L of glucose-6-phosphate. Interpretive criteria are based on the 2014 CLSI breakpoints \[[@pone.0144103.ref021]\]. Decreased ciprofloxacin susceptibility was defined as isolates having ciprofloxacin MIC in the 0.12--1 mg/L range. Susceptibility to cefazolin on urine isolates was determined using the urine and non-urine breakpoints. Susceptibility to tigecycline was interpreted using breakpoints proposed by the European Committee on Antimicrobial Susceptibilities Testing (EUCAST) (<http://www.eucast.org/clinical_breakpoints/>)

Detections of ESBL, AmpC β-lactamase, and carbapenemase genes {#sec006}
-------------------------------------------------------------

The CLSI ESBL confirmatory test was performed on all isolates with aztreonam, ceftazidime, or cefotaxime MIC ≥ 2 mg/L using cefotaxime and ceftazidime disks with and without clavulanate \[[@pone.0144103.ref021]\]. These ESBL screening test-positive isolates were also subject to detection of ESBL and/or AmpC β-lactamases genes by multiplex PCR following previously described primers and protocols \[[@pone.0144103.ref026], [@pone.0144103.ref027]\]. Isolates non-susceptible to carbapenem were subject to carbapenemase PCR using published primers \[[@pone.0144103.ref028]\].

Data analysis {#sec007}
-------------

Susceptibility interpretation analysis was made using the WHONET software \[[@pone.0144103.ref029]\]. Intermediate susceptibility and resistance were grouped together as "non-susceptibility". Duplicate isolates were excluded before analysis. TSAR III and IV (2002--2004), TSAR V and VI (2006--2008), and TSAR VII and VIII (2010--2012) were grouped as Periods I, II, and III, respectively, in the related analysis. Categorical variables were compared using chi-square test or Fisher's exact test (if the number was less than 10). If statistical difference was obtained when the tested categorical variables with three different levels were compared, post-hoc analysis was performed to identify which level was significantly different from the others. Trends were analyzed using chi-square for trend analysis. Multivariable logistic regression analysis was performed to assess the variables (including study year, specimen type, and patient age group) among ESBL or AmpC β-lactamase--producers vs.--non-producers. SAS 9.2 (SAS Institute, Cary, NC, USA) was used for the above analyses. A 2-tailed P value less than 0.05 was considered statistically significant.

Results {#sec008}
=======

Isolates {#sec009}
--------

A total of 3,481 non-duplicate *E*. *coli* isolates were enrolled, with 401, 485, 526, 612, 674, and 783 isolates from TSAR III (2002), IV (2004), V (2006), VI (2008), VII (2010), and VIII (2012), respectively. By geographic regions, a total of 1091, 979, 1004, and 407 isolates were from the northern, central, southern, and eastern parts of Taiwan, respectively. The most common specimen type was urine (2153, 61.9%), followed by blood (1125, 32.3%), and others (203, 5.8%). The age of the source patients was missing in 74 patients. The mean ± standard deviation age of the remaining 3407 patients was 57.4 ± 23.6 years (y), with 6.9% (234) being pediatric patients (≤ 18 y, mean 4.3 y), of whom the majority (195) were younger than 10 years of age, 45.9% being adult (19--64 y, mean 45.0 y), and 47.3% being elderly (≥ 65 y, mean 77 y).

Non-susceptibility to different antimicrobial agents over the study period {#sec010}
--------------------------------------------------------------------------

For ease of comparison, we grouped the 6 study years into 3 periods, with period I, II, III corresponding to 2002--2004, 2006--2008, and 2010--2012, respectively. The rates of overall non-susceptibility of the isolates to various antimicrobial agents from the 3 studied periods are listed in [Table 1](#pone.0144103.t001){ref-type="table"}. Significant increases in non-susceptibility to ciprofloxacin and several β-lactams, including first to fourth generation cephalosporins, aztreonam, and cefoxitin, were noted. In contrast, non-susceptibility to tetracycline and trimethoprim/sulfamethoxazole (SXT) decreased but still remained high, at 59.1% (2006--2008) and 47.2% (2010--2012), respectively. Rates of non-susceptibility to all 4 generations of cephalosporins and ciprofloxacin by each study year are delineated in [Fig 1](#pone.0144103.g001){ref-type="fig"}, which highlights the increasing rates (all *P* \< 0.001) of non-susceptibility over the study years. For example, the overall non-susceptibility to cefotaxime and ciprofloxacin increased from 8.2% and 15% in 2002 to 21.1% and 26.9% in 2012, respectively. Non-susceptibility to cefazolin of isolates from urine also increased from 11.5% in 2002 to 23.9% in 2012. The activities of the different antimicrobial agents against all 3481 *E*. *coli* isolates are presented in [S1 File](#pone.0144103.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0144103.t001

###### Non-susceptibility to different agents and prevalence of ESBL and AmpC-β-lactamase producers in *E*. *coli* isolates from outpatient settings, 2002--2012[^a^](#t001fn001){ref-type="table-fn"}.

![](pone.0144103.t001){#pone.0144103.t001g}

  Antimicrobial agents[^b^](#t001fn002){ref-type="table-fn"}                               Period I                                   Period II   Period III   *P* value[^f^](#t001fn006){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------- ------------------------------------------ ----------- ------------ -------------------------------------------------
  β-lactams:                                                                                                                                                   
   Amoxicillin/CA[^c^](#t001fn003){ref-type="table-fn"}                                    21.2                                       30.1        NT           \<0.001
   Ampicillin                                                                              71.2                                       70.6        69.6         NS
   Aztreonam                                                                               6.4                                        9.9         15.7         \<0.001
   Cefazolin-Non-urine[^d^](#t001fn004){ref-type="table-fn"}                               50.9                                       46.1        60.4         \<0.001
   Cefazolin-Urine[^d^](#t001fn004){ref-type="table-fn"}                                   11.5                                       18.1        23.9         \<0.001
   Cefuroxime                                                                              12.2                                       17.0        22.5         \<0.001
   Cefoxitin                                                                               10.2                                       14.8        17.0         \<0.001
   Cefotaxime                                                                              8.9                                        13.4        19.6         \<0.001
   Ceftazidime                                                                             6.1                                        10.4        13.9         \<0.001
   Cefepime-- 2013                                                                         1.2                                        3.8         7.8          \<0.001
   Cefepime[^e^](#t001fn005){ref-type="table-fn"}                                          2.9                                        5.1         10.6         \<0.001
   Ertapenem[^c^](#t001fn003){ref-type="table-fn"}                                         NT[^c^](#t001fn003){ref-type="table-fn"}   NT          0.8          \-
   Imipenem                                                                                0.1                                        0.2         0.1          NS
   Piperacillin[^c^](#t001fn003){ref-type="table-fn"}                                      69.4                                       69.6        65.4         0.038
   Pip/tazo[^b^](#t001fn002){ref-type="table-fn"},[^c^](#t001fn003){ref-type="table-fn"}   NT                                         4.6         3.9          NS
  Non-β-lactams:                                                                                                                                               
   Amikacin                                                                                1.6                                        1.1         0.8          NS
   Gentamicin                                                                              26.6                                       25.8        24.1         NS
   Ciprofloxacin                                                                           16.4                                       18.6        25.1         \<0.001
   Fosfomycin[^c^](#t001fn003){ref-type="table-fn"}                                        NT                                         NT          0.7          \-
   Nitrofurantoin[^c^](#t001fn003){ref-type="table-fn"}                                    8.3                                        4.8         7.8          NS
   SXT[^b^](#t001fn002){ref-type="table-fn"}                                               55.1                                       50.1        47.2         0.001
   Tetracycline[^c^](#t001fn003){ref-type="table-fn"}                                      64.8                                       59.1        NT           0.01
   Tigecycline[^c^](#t001fn003){ref-type="table-fn"}                                       NT                                         NT          0            \-
   ESBL/AmpC β-lactamase positive:                                                                                                                             
   ESBL                                                                                    4.0                                        4.5         10.7         \<0.001
   AmpC                                                                                    5.3                                        9.1         10.7         \<0.001

^a^ The study was conducted biennially between 2002 and 2012. We grouped the study years into 3 peroids for ease of comparison, with period 1 from 2002 and 2004, period II from 2006 and 2008, and period III from 2010 and 2012.

^b^ Based on the 2014 CLSI breakpoints unless indicated otherwise. CA, clavulanic acid; Pip/tazo, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole.

^c^ These agents were tested on years indicated only: amoxicillin/clavulanate (2002--2008), ertapenem (2012, n = 783), fosfomycin \[2012 urine isolates (n = 461)\], nitrofurantoin \[urine isolates in 2002--2004 (n = 601), 2006 (n = 352), and 2012\], piperacillin \[2002--2008, and 2010 (n = 674)\], tetracycline (2002--2008), tigecycline (2010 & 2012); NT, not tested.

^d^ Separate cefazolin breakpoints for non-urine and urine isolates were used.

^e^ Including the 2014 susceptible dose dependent category (SDD) for cefepime.

^f^ Chi square for trend analysis.

![Increasing non-susceptibility (%) of *E*. *coli* to different agents from community setting, Taiwan, 2002--2012.](pone.0144103.g001){#pone.0144103.g001}

Isolates from different specimen types generally had similar rates of non-susceptibility, with except that isolates from blood had lower non-susceptibility than urine isolates to piperacillin (66.0% vs. 75.2%, *P* = 0.028), piperacillin/tazobactam (2.4% vs. 5.5%, *P* \< 0.001), and ciprofloxacin (18.2% vs. 21.9%, *P* = 0.039) ([Table 2](#pone.0144103.t002){ref-type="table"}). However, significant difference in rates of non-susceptibility to most tested agents existed in isolates from the three age groups, with isolates from elderly patients having the highest rates of non-susceptibility than those from adult and pediatric patients. These included (elderly vs. adult) all 4 generations of cephalosporins (using cefotaxime as example: 20.0% vs. 10.6%, P \<0.001), cefoxitin (19.8% vs. 10.1%, P \< 0.001), and non-β-lactams amikacin (1.6% vs. 0.6%, P = 0.002), gentamicin (29.6% vs. 21.2%, P \< 0.001), and ciprofloxacin (27.6% vs. 15.2%, P \< 0.001) ([Table 2](#pone.0144103.t002){ref-type="table"}). Although isolates from elderly patients had the highest rates of non-susceptibility to most agents, the increase of non-susceptibility to extended-spectrum cephalosporins occurred in isolates from all age groups. Of note, rates of non-susceptibility of pediatric isolates were either higher than or similar to those from adult patients, except ciprofloxacin, which differed slightly (10.7% vs. 15.2%, *P* = 0.067). In addition, isolates from pediatric patients had significantly higher rate of non-susceptibility to amoxicillin/clavulanate than those from the adult patients (30.7% vs. 22.4%, *P* = 0.014).

10.1371/journal.pone.0144103.t002

###### Non-susceptibility (%) of outpatient *E*. *coli* stratified by specimen types, age groups, and geographic regions (2002--2012 combined).

![](pone.0144103.t002){#pone.0144103.t002g}

  Antimicrobial agents[^a^](#t002fn001){ref-type="table-fn"}   Specimen types   Age groups    Geographic regions                                                                                                                 
  ------------------------------------------------------------ ---------------- ------------- -------------------- ------- ------------ ------------- ------------ --------- ------------ ------------ ------------ ------------ ---------
  **β-lactams:**                                                                                                                                                                                                                 
  Amoxicillin/CA[^b^](#t002fn002){ref-type="table-fn"}         24.6 (586)       27.5 (1307)   20.6 (131)           NS      30.7 (150)   22.4 (913)    29.9 (892)   0.001     22.9 (625)   32.7 (556)   25.0 (601)   23.1 (242)   \<0.001
  Ampicillin                                                   68.7             70.7          75.4                 NS      73.5         68.3          72.2         NS        66.4         74.4         71.3         68.8         \<0.001
  Aztreonam                                                    11.6             11.5          9.8                  NS      6.0          8.1           15.7         \<0.001   8.8          13.7         13.0         9.1          \<0.001
  Cefazolin                                                    53.9             55.2          52.7                 NS      55.1         49.5          60.1         \<0.001   50.2         57.5         57.0         54.1         0.003
  Cefazolin-urine                                                               18.6                               \-      15.7 (209)   12.0 (1001)   26.5 (892)   \<0.001   14.4 (716)   25.6 (570)   19.1 (643)   12.1 (224)   \<0.001
  Cefuroxime                                                   18.5             18.0          16.7                 NS      12.0         12.9          24.0         \<0.001   14.5         22.1         20.1         13.0         \<0.001
  Cefoxitin                                                    14.3             15.0          10.8                 NS      8.5          10.1          19.8         \<0.001   13.5         16.3         16.0         9.3          0.003
  Cefotaxime                                                   15.2             14.9          12.8                 NS      8.5          10.6          20.0         \<0.001   11.5         19.1         16.1         10.6         \<0.001
  Ceftazidime                                                  11.2             10.7          8.9                  NS      5.6          7.6           14.6         \<0.001   8.5          13.1         12.4         7.1          \<0.001
  Cefepime                                                     6.8              7.0           6.4                  NS      3.8          5.2           9.1          \<0.001   4.4          10.4         7.2          4.7          \<0.001
  Piperacillin                                                 66.0             70.4          75.2                 0.028   72           68.4          69.9         NS        66.1         73.2         69.0         67.2         0.04
  Pip/tazo[^b^](#t002fn002){ref-type="table-fn"}               2.4              5.5           1.0                  0.001   2.9          3.2           5.3          0.046     3.0          6.0          4.7          1.3          0.005
  **Non-β-lactams:**                                                                                                                                                                                                             
  Amikacin                                                     1.0              1.2           0.5                  NS      0            0.6           1.6          0.002     1.0          1.5          0.9          0.5          NS
  Gentamicin                                                   23.4             26.0          28.1                 NS      23.6         21.2          29.6         \<0.001   21.9         27.4         27.6         23.6         0.006
  Ciprofloxacin                                                18.2             21.9          22.2                 0.039   10.7         15.2          27.6         \<0.001   17.7         23.0         23.2         17.4         \<0.001
  SXT[^b^](#t002fn002){ref-type="table-fn"}                    49.1             50.4          53.2                 NS      52.6         45.9          53.7         \<0.001   46.8         52.6         52.4         47.4         0.016
  **ESBL/AmpC prevalence:**                                                                                                                                                                                                      
  ESBL                                                         6.9              7.0           6.4                  NS      3.9          4.9           9.4          \<0.001   4.6          10.4         7.1          4.7          \<0.001
  AmpC                                                         9.7              8.5           6.4                  NS      3.9          5.9           12.4         \<0.001   7.0          10.7         10.1         5.9          0.002

^a^ Not all agents were tested on all isolates in all years. For those agents not tested on all isolates, the numbers of isolates tested in each stratum are shown below the non-susceptibility percentages. Data on fosfomycin, nitrofurantoin, and tetracycline are not shown in this Table because there were no significant differences in rates of non-susceptibility between the variables in each stratum.

^b^ CA, clavulanic acid; Pip/tazo, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole.

^c^ P value of overall distribution among three groups; NS, Not significant (p \>0.05). The post-hoc analysis results of specimen and age categories are presented in Results section.

Rates of non-susceptibility also differed significantly between isolates from the 4 geographic regions, with those from central and southern regions having the higher rates of non-susceptibility while those from the northern and eastern regions were lower ([Table 2](#pone.0144103.t002){ref-type="table"}). For example, non-susceptibility to cefotaxime was 11.5%, 19.1%, 16.1%, and 10.6%, and to gentamicin was 21.9%, 27.4%, 27.6%, and 23.6% in isolates from the northern, central, southern, and eastern regions, respectively. These differences are also reflected in the prevalence of ESBL and AmpC--producers ([Table 2](#pone.0144103.t002){ref-type="table"}).

Between 2002 and 2012, non-susceptibility to cefotaxime increased from 3.4 to 15.6% (P = 0.092), 5.4 to 17.1% (*P* \< 0.001), and 13.3 to 25.8% (*P* \< 0.001) in isolates from pediatric, adult, and elderly patients, respectively ([Fig 2](#pone.0144103.g002){ref-type="fig"}). Significant increase in ciprofloxacin non-susceptibility also occurred in isolates from adult (from 10.8% to 20.2%, *P* = 0.001) and elderly (from 20.9% to 34.5%, *P* \< 0.001) patients ([Fig 2](#pone.0144103.g002){ref-type="fig"}). However, based on ciprofloxacin MIC distribution, decreased ciprofloxacin susceptibility (DCS) (considered those with ciprofloxacin MIC 0.12--1 mg/L) of isolates from pediatric patients was as high (25.8%) as those from adult (24.8%) and elderly (24.0%) patients ([Fig 3](#pone.0144103.g003){ref-type="fig"}).

![Non-susceptibility (%) of outpatient *E*. *coli* from different age groups to cefotaxime (top) and ciprofloxacin (bottom), Taiwan, 2002--2012.\
Pediatric, ≤18 y.o.; adult, 19--64 y.o.; elderly, ≥ 65 y.o. The number of isolates for each age group in 2002, 20024, 2006, 2008, 2010, and 2012 was 29, 42, 41, 38, 39, and 45, respectively for pediatric patients; 186, 228, 245, 254, 304, and 346, respectively for adult patients; and 158, 211, 229, 294, 326, and 392, respectively, for elderly patients.](pone.0144103.g002){#pone.0144103.g002}

![Ciprofloxacin MIC distribution of outpatient *E*. *coli* isolates from different age groups.\
Data were based on 234 isolates from pediatric, 1563 isolates from adult, and 1610 isolates from elderly patients.](pone.0144103.g003){#pone.0144103.g003}

Four isolates had low-level imipenem non-susceptibility \[2 isolates had MIC 2 ug/mL (intermediate) and 2 isolates had MIC 4 ug/mL (resistant)\]. Carbapenemase (IMP-type) was detected in only 1 of these isolates (data not shown). All isolates were susceptible to tigecycline. Non-susceptibility of the urine isolates to nitrofurantoin remained below 8% over the study years, while only 0.7% (3/461) was nonsusceptible to fosfomycin in the 2012 collection we studied. For the 2153 urine isolates, rates of non-susceptibility to cefazolin differed significantly using the 2014 non-urine (55.2%) and urine interpretive criteria (18.6%) (*P* \<0.001). The new 2014 cefepime breakpoints had a small but significant effect on the overall non-susceptibility (old breakpoints: 4.8% vs. 2014 breakpoints: 6.9%, average of all 6 study years, P \<0.001).

Prevalence, types, and susceptibilities of ESBL and AmpC β-lactamases producers {#sec011}
-------------------------------------------------------------------------------

There were 547 isolates with aztreonam, ceftazidime, and/or cefotaxime MIC ≥ 2 mg/L. These isolates were subject to ESBL phenotypic confirmatory test plus genotypic detection of ESBL and AmpC β-lactamase genes by PCR. Among these 547 isolates, 190 were positive for ESBL genes only (ESBL-pos/AmpC-neg), 254 were positive for AmpC genes only (ESBL-neg/AmpC-pos), and 52 were positive for both ESBL and AmpC genes (ESBL-pos/AmpC-pos) by PCR. Of note, 16 of the 52 PCR ESBL-pos/AmpC-pos isolates had negative ESBL phenotypic confirmatory test. Therefore, the overall false-negative ESBL phenotypic confirmatory test rate was 6.6% (16/242).

Based on PCR results, the prevalence of ESBL-producers remained similar in earlier years (4.0% in 2002--2004 and 4.5% in 2006--2008) but increased to 10.7% in 2010--2012 (P \< 0.001), whereas AmpC-producers increased steadily from 5.3% in 2002--2004, to 9.1% in 2006--2008 and 10.7% in 2010--2012 (P \< 0.001) ([Table 1](#pone.0144103.t001){ref-type="table"}). Among the 242 ESBL-producers, 233 (96.3%) carried CTX-M-type genes, and 12 carried SHV-type genes including 3 that carried both CTX-M- and SHV -type genes. Of the 306 AmpC-producers, 295 (96.4%) carried CMY-type genes, 11 carried DHA-type genes, including 7 that carried both CMY- and DHA- type genes. Compared to isolates that were negative for both ESBL and AmpC by PCR (ESBL-neg/AmpC-neg), isolates positive for either ESBL and/or AmpC were significantly more non-susceptible to most β-lactam as well as non-β-lactam agents ([Table 3](#pone.0144103.t003){ref-type="table"}).

10.1371/journal.pone.0144103.t003

###### Non-susceptibility[^a^](#t003fn001){ref-type="table-fn"} (%) to key agents among *E*. *coli* isolates with and without ESBL or AmpC β-lactamases genes.

![](pone.0144103.t003){#pone.0144103.t003g}

  Antimicrobial agents[^b^](#t003fn002){ref-type="table-fn"}   Combination of ESBL/AmpC gene status                         
  ------------------------------------------------------------ -------------------------------------- ----------- --------- ----------
  Amikacin                                                     23.1                                   7.4         2.8       0.1
  Aztreonam                                                    98.1                                   73.7        74.4      0.6
  Cefoxitin                                                    100                                    29.5        99.2      4.9
  Cefotaxime                                                   100                                    100         97.2      0.9
  Ceftazidime                                                  100                                    35.3        94.5      0.5
  Cefepime (R/SDD)[^c^](#t003fn003){ref-type="table-fn"}       76.9/15.4                              64.7/25.8   0.8/5.5   0.03/0.1
  Ciprofloxacin                                                94.2                                   73.7        63.0      12.5
  Gentamicin                                                   84.6                                   62.2        57.9      19.1

^a^ Non-susceptibility results are based on the 2014 CLSI interpretive criteria.

^b^ Data shown on selected agents that were tested on all isolates.

^c^ Cefepime results are shown in resistant and susceptible dose dependent (SDD) categories.

Using the current CLSI interpretive criteria, all 242 ESBL-positive isolates were non-susceptible to cefotaxime, and all but 7 of the 254 ESBL-neg/AmpC-pos isolates were also non-susceptible. Therefore, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of cefotaxime non-susceptibility in predicting the presence of ESBL and/or AmpC -producers was 98.6%, 99.1%, 94.6%, and 99.8%, respectively. However, 137 (27.6%) of these 496 ESBL and/or AmpC-positive isolates remained susceptible to ceftazidime so the sensitivity, specificity, PPV, and NPV of ceftazidime non-susceptibility in predicting the presence of ESBL and/or AmpC--producers was 72.4%, 99.5%, 96.0%, and 95.6%, respectively, even with the revised lower CLSI breakpoints \[[@pone.0144103.ref021]\]. Of note, significant difference in cefepime non-susceptibility existed in ESBL-positive isolates (92.3% of ESBL-pos/AmpC-pos and 90.5% of ESBL-pos/AmpC-neg isolates) and ESBL-neg/AmpC-pos isolates (6.3%), which included 15.4%, 25.8%, and 5.5% of the ESBL-pos/AmpC-pos, ESBL-pos/AmpC-neg, and ESBL-neg/AmpC-pos isolates with cefepime MIC in the 2014 new susceptible-dose dependent category ([Table 3](#pone.0144103.t003){ref-type="table"}) \[[@pone.0144103.ref021]\].

Statistical analysis to identify factors associated with ESBL and AmpC-β-lactamase producers {#sec012}
--------------------------------------------------------------------------------------------

By univariate analysis, factors associated with carriage of ESBL and AmpC included age, geographic origin of bacterial isolates, and TSAR study period ([Table 4](#pone.0144103.t004){ref-type="table"}). By multivariate analysis, age (elderly vs. pediatric patients), geographic origin (central Taiwan vs. eastern Taiwan) and later study years (2010 and 2012 vs. 2002) remained independent factors associated with ESBL gene carriage ([Table 4](#pone.0144103.t004){ref-type="table"}). Age (elderly vs. pediatric patients), geographic origin (southern, central Taiwan vs. eastern Taiwan) and study period (2006 to 2012 vs. 2002) were also independent factors associated with carriage of AmpC β-lactamase ([Table 4](#pone.0144103.t004){ref-type="table"}).

10.1371/journal.pone.0144103.t004

###### Factors associated with carriage of ESBL and AmpC β-lactamases genes in *E*. *coli*.

![](pone.0144103.t004){#pone.0144103.t004g}

  Strata                                                 ESBL      AmpC β-lactamase                                                        
  ------------------------------------------------------ --------- ------------------ ------------ --------- --------- ------ ------------ ---------
  Study year (using TSAR III \[2002\] as baseline)                                                                                         
   TSAR IV (2004)                                        0.456     0.77               0.39--1.52   NS        0.116     1.64   0.88--3.05   NS
   TSAR V (2006)                                         0.135     0.55               0.27--1.13   NS        0.031     1.85   1.02--3.38   0.044
   TSAR VI (2008)                                        0.287     1.31               0.73--2.35   NS        \<0.001   2.68   1.52--4.72   \<0.001
   TSAR VII (2010)                                       0.019     1.81               1.05--3.14   0.034     \<0.001   3.30   1.90--5.74   \<0.001
   TSAR VIII (2012)                                      \<0.001   3.02               1.79--5.10   \<0.001   0.003     2.21   1.26--3.87   0.006
  Age groups (using Pediatric as baseline)                                                                                                 
   Adult patients                                        0.776     0.98               0.54--1.78   NS        0.354     1.27   0.71--2.27   NS
   Elderly patients                                      0.007     1.93               1.09--3.42   0.024     \<0.001   2.84   1.62--4.98   \<0.001
  Specimen types (using urine as baseline)                                                                                                 
   Blood                                                 0.932                                               0.277                         
   Others                                                0.744                                               0.295                         
  Geographic region (using eastern region as baseline)                                                                                     
   Northern                                              0.98      1.02               0.59--4.27   NS        0.461     1.24   0.77--2.00   NS
   Central                                               \<0.001   2.56               1.53--1.76   \<0.001   0.006     1.99   1.25--3.17   0.004
   Southern                                              0.097     1.63               0.96--2.75   NS        0.014     1.80   1.13--2.86   0.014

^a^ *P* value by univariate analysis. Only variables having statistical significant difference by univariate analysis were subject to multivariate analysis.

^b^ *P* value by multivariate analysis; OR, odds ratio; CI, confidence interval

Discussion {#sec013}
==========

The present study analyzed data from a nationwide surveillance program and revealed that over the past decade (2002 to 2012), significant increase in non-susceptibility to most β-lactam agents and ciprofloxacin occurred in *E*. *coli* isolates from community settings (outpatients and patients visiting emergency rooms) in Taiwan. In addition, non-susceptibility of our 2010--2012 isolates to several agents were higher than those from similar time periods in western countries, including cefazolin (59.7% against 27.7% in Canada), cefotaxime (19.6% against lower than 10% in Canada, USA, and Europe, and lower than 7.4% in UK based on non-susceptibility to 3^rd^ generation cephalosporins, gentamicin (24,1% against 9.8% in Canada and lower than 6% in UK), and trimethoprim/sulfamethoxazole (47.2% against lower than 27.4% in Canada and Europe), even though some of those studies included isolates from inpatients \[[@pone.0144103.ref008], [@pone.0144103.ref019], [@pone.0144103.ref020], [@pone.0144103.ref030]\].

The increased non-susceptibility to nearly all broad-spectrum β-lactams (except imipenem) in our isolates correlated with the increased ESBL- and AmpC β-lactamase-producers, which increased to 10.7% for both, respectively, in 2010--2012. Although increased prevalence of ESBL-producing *E*. *coli* has been noted in several countries \[[@pone.0144103.ref031]\], the 10.7% prevalence of ESBL and AmpC -producers in our 2010--2012 isolates was higher than recent reports on isolates from community settings in USA (ESBL: 5.9%, AmpC-producers: around 0.6%), and Canada (AmpC: 2.6%), and from combination of community and healthcare-associated settings in Canada (ESBL: 5.4%) and northern European countries (ESBL: around 5%, AmpC: 0--3.8%) \[[@pone.0144103.ref008], [@pone.0144103.ref011], [@pone.0144103.ref012], [@pone.0144103.ref015], [@pone.0144103.ref020], [@pone.0144103.ref030]--[@pone.0144103.ref033]\].

In the present study, most ESBL genes were CTX-M types (96.3%), and the predominant AmpC β-lactamases genes was the CMY type (90.7%). Prior studies have shown that the most prevalent ESBL and AmpC enzymes types worldwide, including Taiwan, were CTX-M and CMY types, respectively \[[@pone.0144103.ref034]--[@pone.0144103.ref036]\]. Since only a few isolates had low level non-susceptibility to ertapenem and/or imipenem. Carbapenemase (IMP-type) was detected only in 1 isolate (data not shown). Thus carbapenemase producing *E*. *coli* appeared not to be a major problem in community settings in Taiwan yet.

CLSI lowered the susceptibility breakpoints of third-generation cephalosporins for *Enterobacteriaceae* in 2010 to facilitate the identification of ESBL- and/or AmpC- β-lactamases -producing isolates \[[@pone.0144103.ref037]\]. By applying the revised breakpoints, nearly all (98.7%) of our ESBL and/or AmpC positive isolates were non-susceptible to cefotaxime, yet only 77.6% of them were non-susceptible to ceftazidime. Thus cefotaxime is a better predictor for ESBLs and/or AmpC β-lactamase-producers than ceftazidime in terms of sensitivity (98.7% vs. 77.6%). These results are similar to prior studies \[[@pone.0144103.ref023], [@pone.0144103.ref038], [@pone.0144103.ref039]\], and reflects the predominance of CTX-M since this enzyme hydrolyzes cefotaxime more efficiently than ceftazidime \[[@pone.0144103.ref040]\].

Of noteworthy is that 16 of the 52 PCR ESBL-pos/AmpC-pos isolates in the present study tested negative by the CLSI phenotypic ESBL confirmatory test so the overall false-negative phenotypic ESBL confirmatory test rate was 6.6% (16/242). Co-carriage of ESBL and AmpC β-lactamase genes has become common among Enterobacteriaceae in our region \[[@pone.0144103.ref023], [@pone.0144103.ref036]\]. It has been demonstrated that the presence of AmpC β-lactamases could mask the underlying ESBLs by traditional phenotypic confirmatory test \[[@pone.0144103.ref041]\]. Our result echoes this finding and lends support to using the revised CLSI breakpoints to avoid missing ESBL-producers by the phenotypic ESBL confirmatory test.

Based on the 2014 revised cefepime breakpoints, over 90% of the ESBL producers are non-susceptible to cefepime including 23.6% with cefepime MIC in the susceptible dose dependent range, indicating that higher dosing regimens are needed if cefepime was used for these isolates \[[@pone.0144103.ref021]\]. Significant difference on non-susceptibility to cefazolin in the non-urine (60.4%) vs. urine isolates (23.9%) from the 2010--2012 isolates exists using the 2014 cefazolin non-urine and urine breakpoints. This information is important in antibiotic selection for uncomplicated UTI also.

Non-susceptibility to ciprofloxacin in our 2010--2012 isolates (25.1%) was much higher than that of community *E*. *coli* isolates from the 15.5% (UTI hospital and community isolates combined from 2013) reported in UK \[[@pone.0144103.ref019]\] and other countries in Europe (0.5--7.6% in 2007--2008) \[[@pone.0144103.ref020]\], but was lower than the rate (32.4%) found by a multicenter surveillance of 2009--2011 *E*. *coli* from inpatients with community-acquired UTI in USA \[[@pone.0144103.ref008]\]. Whether such differences were dependent on patient age is unknown since isolates from elderly patients in our study had the highest rate of ciprofloxacin non-susceptibility, which reached 34.5% in 2010--2012.

Isolates from recent years were more likely to carry ESBL and AmpC β-lactamase genes, and these isolates were most likely to be found in elderly patients as well as those from central or southern Taiwan (compared to those from eastern Taiwan). Elderly patients probably had more recent exposure to medical care and antibiotics, resided in long-term care facilities, which have been associated with acquisition of drug-resistant bacteria \[[@pone.0144103.ref015], [@pone.0144103.ref042]--[@pone.0144103.ref044]\]. This in turn would explain why isolates from elderly patients were more resistant than those from adult and pediatric patients. The reason for isolates from central and southern Taiwan being more likely to carry ESBL and AmpC β-lactamase genes, and thus more non-susceptible to most agents, needs further investigation.

We also showed that isolates from pediatric patients had higher rates of non-susceptibility to amoxicillin/clavulanic acid than those from adults and elderly. In addition, the pediatric isolates had similarly high rate (near 25%) of decreased ciprofloxacin susceptibility (DCS, ciprofloxacin MIC 0.12--1 mg/L), probably due to single mutation in the quinolone-resistance-determining region of the drug target or the presence of plasmid-mediated quinolone resistance determinants \[[@pone.0144103.ref045]--[@pone.0144103.ref047]\]. This is a cause for additional concern since the effectiveness of FQ in treating patients infected with DCS isolates may be compromised \[[@pone.0144103.ref047]--[@pone.0144103.ref049]\]. The reasons for the high rates of DCS and amoxicillin/clavulanic acid in the pediatric population needs further study.

Prior reports have pointed out that inappropriate empirical therapy was associated with added mortality among critically ill patients with severe infection \[[@pone.0144103.ref004], [@pone.0144103.ref050]\]. Therefore it has been suggested that the empirical antibiotic therapy for patients with severe infection should cover more than 90% spectrum of all the possible bacterial etiology \[[@pone.0144103.ref051]\]. For community uncomplicated UTI, the suggested prevalence of resistance threshold above which the agent is not recommended was 20% for SXT and 10% for fluoroquinolones \[[@pone.0144103.ref005]\]. Given our study results, cefotaxime might no longer be a reasonable empirical antibiotic for patients with severe community-acquired infections in Taiwan if *E*. *coli* is a probable etiologic agent since around 20% of the isolates from 2010--2012 were cefotaxime-resistant. Similarly, fluoroquinolones are also not appropriate empirical therapy option since non-susceptibility to ciprofloxacin reached 25% in 2010--2012. Instead, ertapenem or cefepime should be considered as the drugs of choice in such situation.

A recent study indicated that nitrofurantoin, an old antimicrobial agent, retained its activity against multidrug resistant *E*. *coli* isolates from the USA, with resistance observed ranging 2.1% to 24.1% of isolates resistant to three to five antimicrobial agents, respectively, with an overall resistance of only 1.2% \[[@pone.0144103.ref009]\]. Our data showed that nitrofurantoin non-susceptibility in urinary *E*. *coli* isolates from Taiwan remained at lower than 8% over the years. Non-susceptibility to fosfomycin was low (lower than 1%) in our 2012 urinary *E*. *coli* isolates. Therefore these 2 older antimicrobial agents could be options for the treatment of uncomplicated cystitis as suggested \[[@pone.0144103.ref005]\].

One limitation of the present study is that since we only have minimum clinical information on the source patients, we could not determine if other independent factors, such as prior antimicrobial use or hospitalization, exist for ESBL and/or AmpC--producers \[[@pone.0144103.ref015], [@pone.0144103.ref042], [@pone.0144103.ref043]\]. However, we did show age (elderly) to be an independent factor for ESBL and AmpC--producers, thus prior hospitalization and more antimicrobial use are likely associated factors. Another limitation is that our isolates were collected biennially during a three months period. However, these isolates were from a total of 28 hospitals located in all four geographical regions of Taiwan, and 25 of them, including 11 medical centers and 14 regional hospitals, participated in all 6 rounds of TSAR between 2002 and 2012. Therefore the results described here can be a representation of the *E*. *coli* from community settings in Taiwan.

In conclusion, this decade-long multicenter surveillance revealed significant increase in non-susceptibility to several broad spectrum antimicrobial agents, including cefotaxime and ciprofloxacin, occurred in *E*. *coli* from community settings in Taiwan. Therefore, multidrug resistance is prevalent not only in healthcare settings but also in the community in our region. The prevalence of ESBL- and AmpC β-lactamase-producing *E*. *coli* also increased significantly, especially in elderly patients. Whether such increase was due to clonal spread or horizontal gene transfer requires further study. The additional high rates of decreased ciprofloxacin susceptibility in *E*. *coli* isolates from all age groups are also a cause for concern. Identification of community reservoirs of the resistant bacteria may help to halt their spread. Finally, our data indicated that there is a need to re-evaluate appropriate treatment selection for community-acquired infections.
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